RARE CANCER    

updates

STAY UP TO DATE on new developments

SHEPHERD Therapeutics and Mayo Clinic Announce Collaboration


SHEPHERD Therapeutics announces its collaboration with Mayo Clinic clinicians and researchers to identify mechanisms for drug response and resistance in rhabdomyosarcoma (RMS) patients, and to identify new single drug and multi-drug combinations that have the potential to impact RMS care.

 

Read more here.

SHEPHERD Therapeutics Announces Research Collaboration with National Institutes of Health's (NIH)


SHEPHERD Therapeutics announces its collaboration with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health. This partnership will identify drugs and drug combinations from NCATS’ annotated compound libraries that may have the potential to significantly improve treatment options and outcomes for patients with adenoid cystic carcinoma, a rare head and neck cancer.

 

Read more here.

SHEPHERD Therapeutics and Oncoheroes Biosciences to Partner for the Discovery, Development and Commercialization of Oncology Therapeutics For Rare Cancers

SHEPHERD Therapeutics announces its partnership with Oncoheroes Biosciences in the discovery, development and commercialization of innovative drug products for rare oncology indications, starting with Oncoheroes’ lead asset, Volasertib.

 

Read more here

RACE for Children Act


As of August 18, 2020, The RACE for Children Act (Research to Accelerate Cures and Equity for Children Act) will be fully implemented. Congratulations to Kids V Cancer and the work of others in driving this change!

 The Race for Children Act now requires all adult cancer therapies in development, whose molecular target is substantially relevant to a pediatric cancer, to be studied in children's cancers as well.

Learn more
here

21st Century Cures 2.0


In April, US Rep. Diana DeGette (D-CO) and Fred Upton (R-MI) released a concept paper for their bipartisan “Cures 2.0.” This legislation builds on the 21st Century Cures Act (P.L. 114-255) passed in 2016, which focused on medical research and new treatments.

Themes that Cures 2.0 will likely focus on include patient engagement in health care decision-making, diversity in clinical trials, and FDA modernization, among others.

Learn more
here

Advancing Access to Precision Medicine Act


Last September, Rep. Eric Swalwell (D-CA) introduced the bipartisan Advancing Access to Precision Medicine Act to push forward use of genetic and genomic testing to improve and save lives.

Learn more
here

TargetCancer Foundation Announces Rare Cancer Precision Medicine Research Initiative


In August, TargetCancer Foundation (TCF) in partnership with Foundation Medicine and academic investigators announced the the initiation of the TCF-001 TRACK (Target Rare Cancer Knowledge) Study. This study will provide precision medicine to rare cancer patients and their treating physicians, right in their own communities. Patients will receive comprehensive genomic profiling of tissue and blood, and resulting reports will be provided to a virtual molecular tumor board, who will recommend treatment options. The study is also incorporating remote consent to break down geographic barriers to participation, and allow patients to both consent and continue to be treated locally.

Learn more
here

Oncoheroes Bioscience Announces FDA Rare Pediatric Disease Designation to to volasertib, an investigational treatment for rhabdomyosarcoma

During childhood cancer awareness month Oncoheroes is delighted to announce that the United States Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to volasertib, an investigational treatment for rhabdomyosarcoma being developed at Oncoheroes Biosciences.

“This designation marks an important milestone for Oncoheroes as we are now eligible to receive a priority review voucher at the time of marketing approval of volasertib,” announced today Ricardo Garcia, Oncoheroes’ Founder and CEO.

Learn more here